false
0001971532
0001971532
2026-02-05
2026-02-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 5, 2026
TELOMIR
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Florida |
001-41952 |
|
87-2606031 |
(State or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS Employer
Identification
No.) |
100
SE 2nd St, Suite 2000, #1009
Miami,
Florida 33131
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (786) 396-6723
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | |
| | ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, no par value |
|
TELO |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 – Other Events
Telomir
Pharmaceuticals Reports New Cellular Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Cellular
findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation
instability, and genomic integrity—without relying on cytotoxic mechanisms.
On
February 5, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) reported new findings from preclinical cellular studies evaluating
its lead investigational compound, Telomir-1, in the form of Telomir-Zn.
In
these studies, done in collaboration with Smart Assays Biotechnologies, Telomir-Zn was shown to induce a rapid and coordinated intracellular
redistribution of metals, characterized by increased intracellular zinc levels and a reciprocal reduction in labile ferrous iron.
The effects were dose-dependent, detected within approximately 30 minutes of exposure, sustained over a two-hour period, and observed
without loss of cell confluence or viability in the evaluated cellular models. Zinc accumulation and iron reduction occurred over
similar concentration ranges and timeframes, supporting a coordinated intracellular process rather than independent or nonspecific metal
effects.
Iron
and zinc play fundamentally different roles in cellular biology. Excess labile iron is redox-active and can drive reactive oxygen
species generation, contributing to mitochondrial damage, DNA instability, and dysregulation of metal-dependent epigenetic enzymes.
Zinc, by contrast, is redox-inert and supports chromatin structure, DNA repair, antioxidant defenses, and proper regulation of epigenetic
processes. The observed simultaneous reduction of redox-active iron and enrichment of intracellular zinc suggests a metal-exchange
process that may reduce oxidative stress while stabilizing epigenetic and mitochondrial function.
These
findings are significant because dysregulated metal balance, oxidative stress, and epigenetic instability are shared upstream drivers
of both cancer biology and age-related cellular decline. By demonstrating coordinated zinc–iron modulation, the reported data
support a mechanism that acts at a foundational biological level rather than targeting downstream disease manifestations.
The
Company also reported that it continues to advance a portfolio of ongoing and completed preclinical research programs, including studies
in triple-negative breast cancer models and longevity-focused models. Based on data generated from completed studies, manuscript
submissions to peer-reviewed journals have been initiated, while additional data continue to be generated from ongoing preclinical
studies.
In
addition, the Company reported that it is finalizing IND-enabling activities and currently plans to submit an Investigational New Drug
application in the first quarter of 2026.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
TELOMIR
PHARMACEUTICALS, INC. |
| |
|
| Dated:
February 5, 2026 |
By: |
/s/
Erez Aminov |
| |
Name: |
Erez
Aminov |
| |
Title: |
Chief
Executive Officer |
